Clinical Trials Logo

Recurrent PD-L1+ Malignant Tumors clinical trials

View clinical trials related to Recurrent PD-L1+ Malignant Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT02930967 Recruiting - Clinical trials for Recurrent PD-L1+ Malignant Tumors

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Start date: August 2016
Phase: Phase 1
Study type: Interventional

A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positive tumors . In this single-arm, open-label, one center, dose escalation clinical study, the main purpose is to determine the safety and efficacy of infusion of autologous Chimeric Switch Receptor modified T cells (CSR T) in adult patients with PD-L1 positive, recurrent or metastatic malignant tumors.